CoChat

Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study

Open access
Baba, Ebenezer, Hamade, Prudence, Kivumbi, Harriet, Marasciulo, Maddy, Maxwell, Kolawole, Moroso, Diego, Roca-Feltrer, Arantxa, Sanogo, Adama, Stenstrom Johansson, Joanna, Tibenderana, James, Abdoulaye, Rahila, Coulibaly, Patrice, Hubbard, Eric, Jah, Huja, Lama, Eugene Kaman, Razafindralambo, Lantorina, Van Hulle, Suzanne, Jagoe, George, Tchouatieu, André-Marie, Collins, David, Gilmartin, Colin, Tetteh, Gladys, Djibo, Yacine, Ndiaye, Fara, Kalleh, Momodou, Kandeh, Balla, Audu, Bala, Ntadom, Godwin, Kiba, Alice, Savodogo, Yacouba, Boulotigam, Kodbesse, Sougoudi, Djiddi Ali, Guilavogui, Timothee, Keita, Moussa, Kone, Diakalidia, Jackou, Hadiza, Ouba, Ibrahim, Ouedraogo, Emile, Messan, Halimatou Alassana, Jah, Fatou, Kaira, Markieu Janneh, Sano, Mariama Sire, Traore, Mamadou Chérif, Ngarnaye, Nadine, Elagbaje, Aishatu Yinusa Cassandra, Halleux, Christine, Merle, Corinne, Iessa, Noha, Pal, Shanthi, Sefiani, Houda, Souleymani, Rachida, Laminou, Ibrahim, Doumagoum, Daugla, Kesseley, Hamit, Coldiron, Matt, Grais, Rebecca, Kana, Musa, Ouedraogo, Jean Bosco, Zongo, Issaka, Eloike, Tony, Ogboi, Sonny Johnbull, Achan, Jane, Bojang, Kalifa, Ceesay, Serign, Dicko, Alassane, Djimde, Abdoulaye, Sagara, Issaka, Diallo, Abdoulaye, NdDiaye, Jean Louis, Loua, Kovana Marcel, Beshir, Khalid, Cairns, Matt, Fernandez, Yolanda, Lal, Sham, Mansukhani, Raoul, Muwanguzi, Julian, Scott, Susana, Snell, Paul, Sutherland, Colin, Tuta, Rhosyn, Milligan, Paul · 2020 · The Lancet
Cited by 244

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Seasonal malaria chemoprevention (SMC) aims to prevent malaria in children during the high malaria transmission season. The Achieving Catalytic Expansion of SMC in the Sahel (ACCESS-SMC) project sought to remove barriers to the scale-up of SMC in seven countries in 2015 and 2016. We evaluated the project, including coverage, effectiveness of the intervention, safety, feasibility, drug resistance, and cost-effectiveness. METHODS: For this observational study, we collected data on the delivery, effectiveness, safety, influence on drug resistance, costs of delivery, impact on malaria incidence and mortality, and cost-effectiveness of SMC, during its administration for 4 months each year (2015 and 2016) to children younger than 5 years, in Burkina Faso, Chad, The Gambia, Guinea, Mali, Niger, and Nigeria. SMC was administered monthly by community health workers who visited door-to-door. Drug administration was monitored via tally sheets and via household cluster-sample coverage surveys. Pharmacovigilance was based on targeted spontaneous reporting and monitoring systems were strengthened. Molecular markers of resistance to sulfadoxine-pyrimethamine and amodiaquine in the general population before and 2 years after SMC introduction was assessed from community surveys. Effectiveness of monthly SMC treatments was measured in case-control studies that compared receipt of SMC between patients with confirmed malaria and neighbourhood-matched community controls eligible to receive SMC. Impact on incidence and mortality was assessed from confirmed outpatient cases, hospital admissions, and deaths associated with malaria, as reported in national health management information systems in Burkina Faso and The Gambia, and from data from selected outpatient facilities (all countries). Provider costs of SMC were estimated from financial costs, costs of health-care staff time, and volunteer opportunity costs, and cost-effectiveness ratios were calculated as the total cost of SMC in each country divided by the predicted number of cases averted. FINDINGS: 12 467 933 monthly SMC treatments were administered in 2015 to a target population of 3 650 455 children, and 25 117 480 were administered in 2016 to a target population of 7 551 491. In 2015, among eligible children, mean coverage per month was 76·4% (95% CI 74·0-78·8), and 54·5% children (95% CI 50·4-58·7) received all four treatments. Similar coverage was achieved in 2016 (74·8% [72·2-77·3] treated per month and 53·0% [48·5-57·4] treated four times). In 779 individual case safety reports over 2015-16, 36 serious adverse drug reactions were reported (one child with rash, two with fever, 31 with gastrointestinal disorders, one with extrapyramidal syndrome, and one with Quincke's oedema). No cases of severe skin reactions (Stevens-Johnson or Lyell syndrome) were reported. SMC treatment was associated with a protective effectiveness of 88·2% (95% CI 78·7-93·4) over 28 days in case-control studies (2185 cases of confirmed malaria and 4370 controls). In Burkina Faso and The Gambia, implementation of SMC was associated with reductions in the number of malaria deaths in hospital during the high transmission period, of 42·4% (95% CI 5·9 to 64·7) in Burkina Faso and 56·6% (28·9 to 73·5) in The Gambia. Over 2015-16, the estimated reduction in confirmed malaria cases at outpatient clinics during the high transmission period in the seven countries ranged from 25·5% (95% CI 6·1 to 40·9) in Nigeria to 55·2% (42·0 to 65·3) in The Gambia. Molecular markers of resistance occurred at low frequencies. In individuals aged 10-30 years without SMC, the combined mutations associated with resistance to amodiaquine (pfcrt CVIET haplotype and pfmdr1 mutations [86Tyr and 184Tyr]) had a prevalence of 0·7% (95% CI 0·4-1·2) in 2016 and 0·4% (0·1-0·8) in 2018 (prevalence ratio 0·5 [95% CI 0·2-1·2]), and the quintuple mutation associated with resistance to sulfadoxine-pyrimethamine (triple mutation in pfdhfr and pfdhps mutations [437Gly and 540Glu]) had a prevalence of 0·2% (0·1-0·5) in 2016 and 1·0% (0·6-1·6) in 2018 (prevalence ratio 4·8 [1·7-13·7]). The weighted average economic cost of administering four monthly SMC treatments was US$3·63 per child. INTERPRETATION: SMC at scale was effective in preventing morbidity and mortality from malaria. Serious adverse reactions were rarely reported. Coverage varied, with some areas consistently achieving high levels via door-to-door campaigns. Markers of resistance to sulfadoxine-pyrimethamine and amodiaquine remained uncommon, but with some selection for resistance to sulfadoxine-pyrimethamine, and the situation needs to be carefully monitored. These findings should support efforts to ensure high levels of SMC coverage in west and central Africa. FUNDING: Unitaid.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32227-3

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 244

Metadata

Authors
Baba, E., Hamade, P., Kivumbi, H., Marasciulo, M., Maxwell, K., Moroso, D., Roca-Feltrer, A., Sanogo, A., Stenstrom Johansson, J., Tibenderana, J., Abdoulaye, R., Coulibaly, P., Hubbard, E., Jah, H., Lama, E. K., Razafindralambo, L., Van Hulle, S., Jagoe, G., Tchouatieu, A.-M., Collins, D., Gilmartin, C., Tetteh, G., Djibo, Y., Ndiaye, F., Kalleh, M., Kandeh, B., Audu, B., Ntadom, G., Kiba, A., Savodogo, Y., Boulotigam, K., Sougoudi, D. A., Guilavogui, T., Keita, M., Kone, D., Jackou, H., Ouba, I., Ouedraogo, E., Messan, H. A., Jah, F., Kaira, M. J., Sano, M. S., Traore, M. C., Ngarnaye, N., Elagbaje, A. Y. C., Halleux, C., Merle, C., Iessa, N., Pal, S., Sefiani, H., Souleymani, R., Laminou, I., Doumagoum, D., Kesseley, H., Coldiron, M., Grais, R., Kana, M., Ouedraogo, J. B., Zongo, I., Eloike, T., Ogboi, S. J., Achan, J., Bojang, K., Ceesay, S., Dicko, A., Djimde, A., Sagara, I., Diallo, A., NdDiaye, J. L., Loua, K. M., Beshir, K., Cairns, M., Fernandez, Y., Lal, S., Mansukhani, R., Muwanguzi, J., Scott, S., Snell, P., Sutherland, C., Tuta, R., & Milligan, P.
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-12
Volume
396
Issue
10265
Pages
1829-1840
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3108025284
Cited by
244
References
4
FWCI
20.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32227-3
The paper
Baba, E., Hamade, P., Kivumbi, H., Marasciulo, M., Maxwell, K., Moroso, D., Roca-Feltrer, A., Sanogo, A., Stenstrom Johansson, J., Tibenderana, J., Abdoulaye, R., Coulibaly, P., Hubbard, E., Jah, H., Lama, E. K., Razafindralambo, L., Van Hulle, S., Jagoe, G., Tchouatieu, A.-M., . . . Milligan, P. (2020). Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. The Lancet. https://doi.org/10.1016/s0140-6736(20)32227-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.